New Zealand dairy processor making infant formula and nutritional milk products
Synlait Milk is a Canterbury-based dairy nutrition manufacturer whose stack pairs a deep SAP footprint (S/4HANA, EWM, TM, SD, Signavio) with plant automation on Siemens and Allen-Bradley PLCs plus Ignition. A lab toolset of HPLC, ICP-MS, LC-MS/MS and LIMS reflects regulated infant-formula testing, and accelerating hiring weighted toward manufacturing and quality ties directly to dryer efficiency, validation and SAMR re-registration work.
Synlait Milk Limited is a publicly listed New Zealand company founded in 2000 and headquartered in Dunsandel, Canterbury. It combines farming with dairy processing to produce nutritional milk products, including infant formula, advanced nutrition, foodservice and dairy ingredients, for customers worldwide. The company employs between 1,001 and 5,000 people and positions sustainability as a core operating principle, including B Corp status. Its operations span manufacturing, quality assurance, engineering, operations and finance functions.
Synlait runs SAP S/4HANA with SAP EWM, Transportation Management, SD and Signavio, plant automation on Siemens PLC, Allen-Bradley and Ignition, lab systems like LIMS, HPLC and ICP-MS, plus Power BI, Power Platform, Python and .NET.
Yes. Hiring is accelerating, concentrated in manufacturing and quality roles, with additional openings in engineering, operations, finance and HR, mostly at mid and senior levels.
Synlait Milk is headquartered in Dunsandel, Canterbury, New Zealand, and has operated since its founding in 2000.
Other companies in the same industry, closest in size
Synlait Milk Limited's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.